Study guide

7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy

FEBU Part 1 Written European Board of Urology

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Strategy

1.1 FEBU Part 1 Examination Structure & Logistics 1.2 EAU Guidelines Framework & Standard Setting 1.3 Clinical Decision-Making & MCQ Strategy 1.4 Professionalism and Safe Practice

2 Chapter 2: Genitourinary Anatomy & Renal Physiology

2.1 Upper Tract Anatomy & Retroperitoneal Relationships 2.2 Lower Urinary Tract Anatomy & Neuroanatomy 2.3 Renal Physiology, Glomerular Filtration & Acid-Base Balance

3 Chapter 3: Urological Pharmacology & Diagnostic Imaging

3.1 Lower Urinary Tract Pharmacotherapy 3.2 Antimicrobial Stewardship & Perioperative Care 3.3 Diagnostic Modalities: Ultrasound, CT, mpMRI & Nuclear Medicine

4 Chapter 4: Prostate Cancer: Diagnosis & Risk Stratification

4.1 PSA Kinetics, Biomarkers & Risk Assessment 4.2 Multiparametric MRI (PI-RADS) & Biopsy Strategies 4.3 Histopathological Grading (ISUP Gleason) & Staging

5 Chapter 5: Prostate Cancer: Localized & Advanced Management

5.1 Active Surveillance & Watchful Waiting 5.2 Radical Prostatectomy & Radiation Therapy 5.3 Biochemical Recurrence & Salvage Therapies 5.4 Metastatic & Castration-Resistant Prostate Cancer (CRPC)

6 Chapter 6: Bladder Cancer: Non-Muscle Invasive (NMIBC)

6.1 TURBT Technique & Pathological Staging 6.2 EAU Risk Stratification for NMIBC 6.3 Intravesical Chemotherapy & BCG Immunotherapy

7 Chapter 7: Muscle-Invasive Bladder Cancer & Upper Tract Urothelial Carcinoma

7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy 7.2 Radical Cystectomy & Urinary Diversion 7.3 Upper Tract Urothelial Carcinoma (UTUC)

8 Chapter 8: Renal Cell Carcinoma & Adrenal Neoplasms

8.1 Histological Subtypes, Genetics & Staging of RCC 8.2 Localized RCC: Nephron-Sparing Surgery & Radical Nephrectomy 8.3 Metastatic RCC & Targeted / Immunotherapy Regimens 8.4 Adrenal Masses & Incidentalomas

9 Chapter 9: Testicular Germ Cell Tumours & Penile Cancer

9.1 Testicular Cancer Diagnosis, Staging & Tumour Markers 9.2 Management of Seminoma (Stage I to Metastatic) 9.3 Management of Non-Seminoma (Stage I to Metastatic) 9.4 Penile Cancer: Staging, Organ-Sparing & Lymphadenectomy

10 Chapter 10: Benign Prostatic Hyperplasia & Lower Urinary Tract Symptoms

10.1 BPH Pathophysiology, Natural History & Clinical Evaluation 10.2 Medical Management of Male LUTS / BPO 10.3 Interventional & Surgical Management of BPO

11 Chapter 11: Functional Urology, Incontinence & Neuro-Urology

11.1 Urinary Incontinence in Men and Women, Fistulae & Urethral Diverticula 11.2 Overactive Bladder, Bladder Pain Syndrome & Pelvic Organ Prolapse 11.3 Neurogenic Lower Urinary Tract Dysfunction (NLUTD) 11.4 Urodynamic Studies: Indications, Technique & Interpretation

12 Chapter 12: Urolithiasis: Evaluation & Medical Management

12.1 Stone Pathophysiology & Risk Factors 12.2 Metabolic Evaluation & Dietary/Medical Stone Prevention 12.3 Acute Ureteric Colic & Medical Expulsive Therapy

13 Chapter 13: Endourology & Interventional Stone Management

13.1 Shock Wave Lithotripsy (SWL) 13.2 Ureteroscopy (URS) & Retrograde Intrarenal Surgery (RIRS) 13.3 Percutaneous Nephrolithotomy (PCNL) & Endourological Safety

14 Chapter 14: Infections, Andrology & Male Infertility

14.1 Localised & Systemic UTIs, Pyelonephritis, Urosepsis & Specific Infections 14.2 Prostatitis, Epididymo-Orchitis & Fournier Gangrene 14.3 Male Infertility: Evaluation & Surgical Management 14.4 Erectile Dysfunction, Peyronie Disease, Priapism & Gender-Affirming Surgery

15 Chapter 15: Paediatric Urology, Trauma & Renal Transplantation

15.1 Cryptorchidism, Hypospadias & PUJO 15.2 Vesicoureteral Reflux, Posterior Urethral Valves & Nocturnal Enuresis 15.3 Genitourinary Trauma: Kidney, Bladder & Urethra 15.4 Renal Failure, Dialysis Indications & Renal Transplantation

7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy

Key Takeaways Explain This Topic AI

Muscle-invasive bladder cancer (MIBC) is pathologically defined by malignant infiltration of the detrusor muscle (muscularis propria), staged into T2a (inner superficial half) and T2b (outer deep half), or locally advanced extravesical extension (T3 perivesical fat; T4 adjacent organs or pelvic wall).

Stage MIBC with CT of the chest, abdomen and pelvis, including appropriate upper-tract imaging. MRI/VI-RADS can refine local assessment; EUA and imaging have limitations and do not replace adequate histology.

Perioperative GC plus durvalumab (NIAGARA: 4 neoadjuvant cycles, cystectomy, 8 adjuvant durvalumab cycles) improves EFS and OS and is strongly recommended by EAU for cisplatin- and immunotherapy-eligible cT2–T4aN0–1M0 disease. GFR ≥40 mL/min is allowed, with split-dose cisplatin at 40–59; assess all other fitness criteria.

For suitable cisplatin-ineligible patients, EAU strongly recommends perioperative EV plus pembrolizumab (KEYNOTE-905/EV-303): 3 neoadjuvant combination cycles, surgery, then 6 EV and 14 pembrolizumab cycles. Carboplatin-containing NAC is not recommended because survival benefit is unestablished.

TMT combines maximal safe TURBT, radiosensitizing chemotherapy and radiotherapy. It is best suited to solitary cT2–T3a disease, no extensive/multifocal CIS, no or unilateral hydronephrosis and good bladder function. Surveillance and salvage cystectomy for invasive failure are essential.

Last updated: November 2026

7.1 Muscle-Invasive Bladder Cancer (MIBC) Staging & Neoadjuvant Therapy

Muscle-invasive bladder cancer (MIBC) accounts for approximately 20% to 25% of all newly diagnosed bladder tumors and carries an aggressive natural history with a high propensity for early occult micrometastatic dissemination. Optimal management requires precise pathological characterization, systematic cross-sectional clinical staging, and timely integration of multimodality systemic therapy prior to definitive local extirpation or radiation-based bladder preservation.

1. Clinical Presentation & Initial Assessment

The most common presenting symptom is painless macroscopic (gross) hematuria . Other primary clinical manifestations include:

Irritable Lower Urinary Tract Symptoms (LUTS) : Persistent urgency, frequency, and dysuria in the absence of documented bacterial infection, frequently reflecting extensive trigonal involvement, malignant detrusor irritability, or accompanying diffuse carcinoma in situ (CIS).

Ureteral Obstruction & Flank Pain : Hydroureteronephrosis resulting from tumor infiltration or compression of the intramural ureteric orifice.

Pelvic Symptoms & Mass : Deep aching pelvic or perineal discomfort, lower extremity lymphedema, or a palpable pelvic mass, indicating advanced extravesical extension or extensive pelvic sidewall nodal involvement.

Bimanual Examination Under Anesthesia (EUA)

A structured bimanual examination (one hand on the lower abdomen, index finger in the rectum for men or vagina for women) under full neuromuscular blockade before and after transurethral resection remains a cornerstone of physical staging:

No palpable mass : Compatible with organ-confined disease, but does not exclude extravesical invasion; T3a is microscopic extension beyond the bladder.

Palpable, mobile three-dimensional mass : Suggests macroscopic extravesical invasion (cT3b).

Fixed pelvic mass : Raises concern for pelvic/abdominal wall invasion (cT4b). EUA can under- or overstage disease; interpret it with pathology and imaging.

2. TNM Staging Classification (UICC 9th Edition, 2025)

Current EAU guidance uses the UICC 9th edition; the principal bladder T, N and M categories below are retained from the 8th edition:

Primary Tumour (T Stage)

T2 : Tumor invades the detrusor muscle (muscularis propria).

T2a : Tumor invades the inner (superficial) half of the muscularis propria.

T2b : Tumor invades the outer (deep) half of the muscularis propria.

T3 : Tumor invades perivesical tissue (extravesical extension).

T3a : Microscopically invades perivesical tissue.

T3b : Macroscopically invades perivesical tissue (extravesical mass visible on imaging or EUA).

T4 : Tumor invades adjacent structures.

T4a : Tumor directly invades the prostatic stroma , seminal vesicles, uterus, or vagina.

T4b : Tumor directly invades the pelvic wall or abdominal wall .

Important

Tumor extension from the bladder mucosa directly into the prostatic urethra or prostatic ducts without stromal penetration is classified according to the urethral/bladder tumor stage and does NOT constitute T4a disease. For prostatic involvement, T4a requires direct extension of the bladder primary into prostatic stroma .

Regional Lymph Nodes (N Stage)

Regional lymph nodes include the true pelvic nodes (internal iliac/hypogastric, external iliac, obturator and presacral) and common iliac nodes :

N0 : No regional lymph node metastasis.

N1 : Metastasis in a single regional lymph node in the true pelvis.

N2 : Metastasis in multiple regional lymph nodes in the true pelvis.

N3 : Metastasis in common iliac lymph node(s).

Distant Metastasis (M Stage)

M0 : No distant metastasis.

M1a : Metastasis in any non-regional lymph nodes , such as para-aortic, paracaval, inguinal, mediastinal or supraclavicular nodes; common iliac nodes remain regional (N3).

M1b : Non-lymph node distant metastasis (visceral metastases: lungs, liver, bones, peritoneum, or pleura).

3. Cross-Sectional Diagnostic & Staging Modalities

Accurate staging determines whether a patient is a candidate for curative-intent surgery, neoadjuvant therapy, or palliative systemic interventions.

Contrast-Enhanced Computed Tomography (CECT)

Standard of Care : CT of the chest, abdomen and pelvis is used for MIBC staging, with appropriate contrast/urographic phases to assess abdominal organs and the upper urinary tract.

Thoracic Imaging : Chest CT assesses pulmonary metastases more sensitively than chest radiography. Triphasic acquisition of the chest itself is not required.

Abdominal and Pelvic Imaging : Evaluates the depth of primary tumor infiltration, retroperitoneal and pelvic lymphadenopathy (short-axis lymph node diameter >8 mm in the pelvis or >10 mm in the retroperitoneum is suspicious for metastasis), hepatic metastases, and synchronous upper tract urothelial carcinoma (UTUC).

Pelvic Multiparametric MRI & VI-RADS

Multiparametric MRI (mpMRI) using T2-weighted, diffusion-weighted (DWI), and dynamic contrast-enhanced (DCE) imaging demonstrates superior soft-tissue contrast compared to CT:

VI-RADS (Vesical Imaging-Reporting and Data System) : A standardized 5-point scoring system assessing the structural integrity of the low-signal-intensity muscularis propria on T2-weighted imaging and high-signal restriction on DWI.

Diagnostic Accuracy : EAU cites pooled mpMRI/VI-RADS sensitivity of 83% and specificity of 90% for predicting muscle invasion, with performance dependent on the threshold and setting. If MRI is used for primary local staging, perform it before TURBT. MRI does not replace adequate histological staging or indicated repeat TURBT.

[18F]FDG Positron Emission Tomography / CT (PET/CT)

Urinary FDG excretion limits assessment of the primary bladder tumour. FDG-PET/CT can reveal additional nodal or distant disease in selected patients, but nodal sensitivity is limited despite relatively high specificity: a negative scan cannot exclude microscopic metastases. It supplements rather than replaces standard staging. Routine bone scanning is unnecessary without clinical suspicion of skeletal spread.

  • 4. Neoadjuvant & Perioperative Systemic Therapy
  • Level 1 Evidence & The Evolution of Perioperative Therapy

Randomized controlled trials and the definitive Advanced Bladder Cancer (ABC) Meta-analysis established neoadjuvant cisplatin-based combination chemotherapy as conferring a proven survival advantage:

Overall Survival Benefit : The ABC individual-patient meta-analysis found a 5 percentage-point five-year OS benefit from platinum-based combination NAC (HR 0.86 ); a later analysis cited by EAU found an 8 percentage-point benefit.

Number Needed to Treat (NNT) : At five years, 1 / 0.05 = 20 1/0.05=20 1/0.05 = 20 or 1 / 0.08 = 12.5 1/0.08=12.5 1/0.08 = 12.5 (approximately 13 patients ), depending on the absolute benefit used. Do not combine one analysis's HR with another's absolute result.

Pathological Downstaging : pCR (ypT0N0) is a favourable prognostic finding. In SWOG 8710, no residual bladder tumour was found in 38% versus 15% after neoadjuvant MVAC versus surgery alone; five-year survival in the MVAC pT0 subgroup was 85% , a trial result rather than a universal forecast.

The New Standard of Care: Perioperative Chemoimmunotherapy (NIAGARA Regimen)

The landmark phase III NIAGARA trial demonstrated that adding immune checkpoint inhibition to cisplatin-based chemotherapy across the perioperative period significantly improves oncological outcomes compared to neoadjuvant chemotherapy alone:

Regimen Architecture :

Neoadjuvant Phase : Gemcitabine (1000 mg/m² IV on days 1 and 8) plus cisplatin (70 mg/m² IV on day 1, or split into 35 mg/m² on days 1 and 8) administered concurrently with durvalumab (1500 mg IV on day 1) every 3 weeks for 4 cycles .

Surgical Extirpation : Radical cystectomy with bilateral standard pelvic lymphadenectomy after recovery from neoadjuvant therapy, avoiding unnecessary delay.

Adjuvant Phase : Continuation of durvalumab (1500 mg IV every 4 weeks) for 8 cycles post-operatively.

Trial Outcomes :

Statistically significant improvement in event-free survival (EFS) : Hazard ratio 0.68 (95% CI 0.56–0.82, p < 0.001).

Statistically significant improvement in overall survival (OS) : Hazard ratio 0.75 (95% CI 0.59–0.93, p = 0.01).

An updated pathological complete response analysis found 37.3% versus 27.5% ; the original formal pCR endpoint did not meet its prespecified significance threshold. EFS and OS established the benefit.

Guideline Status : Approved by the EMA and FDA, current EAU Guidelines (2025/2026 Update) assign a Strong Recommendation to offer perioperative chemoimmunotherapy with cisplatin/gemcitabine and durvalumab (NIAGARA regimen) to patients with MIBC (cT2–T4a, cN0–1 M0) who are eligible for cisplatin-based chemotherapy and immunotherapy.

Expanded Renal Eligibility : NIAGARA and current EAU perioperative guidance allow GFR ≥ \ge ≥ 40 mL/min , with cisplatin 35 mg/m² on days 1 and 8 for the 40–59 mL/min group. Assess other fitness criteria and confirm borderline renal estimates; GFR alone does not establish eligibility.

Alternative Cisplatin Regimens (When Immunotherapy is Contraindicated)

When immune checkpoint inhibitors are contraindicated (e.g., severe active autoimmune disorders):

Dose-Dense MVAC (ddMVAC) : Methotrexate, vinblastine, doxorubicin and cisplatin every two weeks with G-CSF support. VESPER compared six ddMVAC cycles with four GC cycles . The overall perioperative three-year PFS comparison (64% versus 56%, p=0.066) did not meet the primary endpoint. In the neoadjuvant subgroup, three-year PFS was 66% versus 56% (HR 0.70, p=0.025); five-year OS was 66% versus 57% (HR 0.71).

Gemcitabine plus Cisplatin (GC) : Gemcitabine on days 1 and 8 plus cisplatin on day 1 (or split days 1 and 8), every 21 days for four cycles. GC remains an accepted NAC regimen. Its favourable toxicity comparison with conventional MVAC in advanced disease does not establish equivalence to six-cycle neoadjuvant ddMVAC.

Timing & Delay Restrictions

Organise cystectomy promptly once the patient has recovered from NAC. EAU advises avoiding delays beyond three months when neoadjuvant treatment is not being given . A planned NAC course is not a breach of that diagnosis-to-surgery rule; avoid unnecessary delays after its completion.

5. Cisplatin Eligibility & Systemic Regimens for Ineligible Patients

Cisplatin is an active, nephrotoxic, neurotoxic and emetogenic platinum agent that crosslinks DNA. The 2011 Galsky consensus defined cisplatin ineligibility for metastatic urothelial carcinoma; perioperative protocols may use different renal thresholds.

Updated Assessment of Cisplatin Eligibility

A patient is traditionally classified as ineligible for cisplatin if they exhibit ANY ONE of the following physiological parameters:

Renal Function : Creatinine clearance < 60 mL/min in the classical consensus.

Contemporary Practice & Protocol Modification : NIAGARA allowed GFR ≥ \ge ≥ 40 mL/min , using split-dose cisplatin (35 mg/m² on days 1 and 8) at 40–59 mL/min. Below 40 mL/min the patient falls outside that regimen's renal eligibility; do not extrapolate it as a universal safety guarantee or ignore hearing, neuropathy, cardiac and performance-status assessment.

Performance Status : Eastern Cooperative Oncology Group (ECOG) performance status ≥ \ge ≥ 2 (or Karnofsky Performance Scale ≤ \le ≤ 70%).

Audiometric Impairment : Documented CTCAE grade ≥ \ge ≥ 2 hearing loss . Grade 2 can occur without a hearing-aid requirement; assess audiometry and functional impact rather than equating grade 2 with grade 3 hearing loss.

Peripheral Neuropathy : Grade ≥ \ge ≥ 2 peripheral neuropathy (sensory loss or paresthesias interfering with ADLs).

Congestive Heart Failure : New York Heart Association (NYHA) functional class ≥ \ge ≥ III (marked limitation of physical activity, comfort only at rest; unable to tolerate intensive pre- and post-cisplatin intravenous hydration).

Systemic Therapy for Cisplatin-Ineligible Patients: Perioperative EV + Pembrolizumab

Historically, cisplatin-ineligible patients with localized MIBC were offered no neoadjuvant systemic therapy and were directed straight to upfront radical cystectomy. This historical paradigm has been overturned by landmark phase III trial evidence:

The KEYNOTE-905 / EV-303 Phase III Trial :

Evaluated perioperative enfortumab vedotin (EV) —an antibody-drug conjugate (ADC) targeting cell-surface Nectin-4 linked to the microtubule-disrupting cytotoxin monomethyl auristatin E (MMAE)—in combination with pembrolizumab (anti-PD-1 checkpoint inhibitor) in surgery-eligible patients with cT2–T4aN0M0 or cT1–T4aN1M0 predominant urothelial cancer who were cisplatin-ineligible or declined cisplatin.

Regimen : Three 21-day neoadjuvant cycles (EV on days 1 and 8, pembrolizumab on day 1), then cystectomy with PLND. Postoperatively give six EV cycles and fourteen pembrolizumab cycles every three weeks: pembrolizumab continues alone after EV finishes.

Outcomes : pCR was 57.1% versus 8.6% , with EFS HR 0.40 and OS HR 0.50 versus surgery followed by observation. These results support the perioperative option for appropriate cisplatin-ineligible patients.

EAU Guideline Recommendation (2025/2026 Update) :

Strong Recommendation : Offer perioperative enfortumab vedotin plus pembrolizumab to patients with MIBC who are ineligible for cisplatin-based chemotherapy, rather than routine upfront cystectomy without consideration of systemic therapy.

Why Carboplatin Is Not Recommended as NAC

Caution

The Carboplatin Rule : Carboplatin-based NAC has no established survival benefit in localized MIBC. Evidence supporting cisplatin cannot be transferred to carboplatin; this is absence of adequate supporting evidence, not proof from multiple randomized carboplatin trials that all benefit is impossible. EAU strongly recommends not offering carboplatin-containing NAC to cisplatin-ineligible patients.

Role of Upfront Radical Cystectomy

Upfront radical cystectomy with bilateral standard pelvic lymphadenectomy remains appropriate when the MDT judges perioperative systemic treatment unsuitable or it is declined, for example:

Patients who are unfit for both cisplatin and enfortumab vedotin plus pembrolizumab (e.g., severe uncontrolled autoimmune disease, severe pre-existing peripheral neuropathy, uncontrolled poorly managed diabetes precluding EV, or ECOG performance status ≥ \ge ≥ 3).

Patients who decline perioperative systemic therapy.

Adjuvant Immunotherapy for High-Risk Pathological Disease

After surgery without neoadjuvant systemic therapy, offer cisplatin-based adjuvant combination chemotherapy to fit patients with pT3/4 and/or pN+ disease. For patients unsuitable for or declining adjuvant cisplatin, discuss one year of nivolumab for high-risk disease: pT3/4 and/or pN+ without NAC , or ≥ \ge ≥ ypT2N0/ypN+ after NAC . CheckMate 274 improved DFS versus placebo in the overall and PD-L1-positive populations. EU authorisation requires tumour-cell PD-L1 ≥ \ge ≥ 1%; FDA approval does not. Do not automatically add nivolumab to an already planned perioperative checkpoint-inhibitor regimen.

6. Trimodal Therapy (TMT) for Bladder Preservation

Trimodal therapy (TMT) represents an evidence-based, oncologically valid alternative to radical cystectomy for carefully selected patients who prioritize bladder preservation or possess prohibitive surgical comorbidities.

The Three Components of TMT

Maximal TURBT : Resect as much visible tumour as safely possible, ideally achieving complete macroscopic clearance. A TURBT does not certify the circumferential surgical margins of a cystectomy specimen.

Radiosensitizing Chemotherapy : Concurrent administration of radiosensitizing chemotherapeutic agents—typically cisplatin plus 5-fluorouracil (5-FU), mitomycin C plus 5-FU (BC2001 trial protocol), or weekly low-dose cisplatin.

External Beam Radiotherapy (EBRT) : Conventional treatment gives 40–45 Gy initially and a boost to 60–66 Gy to the bladder/tumour bed. Elective pelvic nodal irradiation is optional in cN0 disease. 55 Gy in 20 fractions is an accepted bladder-only alternative.

Candidate Selection Criteria

Selection strongly influences outcome; local response, bladder-intact survival and overall survival are different endpoints. Favourable features include:

Solitary / Unifocal Tumor : Usually cT2–T3a , with a smaller, completely resectable tumour most favourable.

No or Unilateral Hydronephrosis : Hydronephrosis is an adverse feature; selected unilateral cases remain candidates, whereas bilateral obstruction is less favourable.

Absence of Extensive Carcinoma in Situ (CIS) : Extensive or multifocal CIS increases the risk of urothelial recurrence and makes bladder preservation less favourable.

Good Baseline Bladder Function & Capacity : Normal functional capacity without severe baseline urge incontinence, small-capacity spastic bladder, or severe refractory LUTS.

Completeness of Initial Resection : Complete macroscopic clearance achieved at the preliminary TURBT.

Split-Course vs Continuous Protocols & Salvage Cystectomy

Historical split-course regimens reassess response with cystoscopy/biopsy after induction chemoradiation; complete responders proceed to consolidation. Continuous-course treatment is now standard , with response assessment after completion.

Persistent or recurrent muscle-invasive disease requires prompt evaluation for salvage cystectomy in fit patients. Selected non-muscle-invasive recurrences may instead be managed with TURBT and appropriate intravesical treatment.

All TMT patients need lifelong bladder surveillance; a clinical complete response is not a cystectomy-proven pathological response.

  • 7. Staging and Decision-Making Pathways
  • Contemporary Physiological Stratification for Systemic Therapy

Physiological Parameter Cisplatin-Eligible Criteria Borderline / Split-Dose Criteria Cisplatin-Ineligible Criteria & Alternative Strategy

Renal Function (GFR) GFR ≥ \ge ≥ 60 mL/min (Standard single-day cisplatin: 70 mg/m²) eGFR 40–59 mL/min (Eligible for split-dose cisplatin : 35 mg/m² days 1 & 8, e.g., NIAGARA) GFR < 40 mL/min : Outside NIAGARA renal eligibility; assess EV + pembrolizumab suitability or another definitive approach.

Performance Status ECOG 0–1 ECOG 1 ECOG ≥ \ge ≥ 2 : Generally cisplatin-ineligible; selected ECOG 2 patients may receive EV + pembrolizumab. Assess fitness for any systemic/local treatment.

Audiometric Status Normal hearing or Grade 1 impairment Grade 1 impairment Grade ≥ \ge ≥ 2 hearing loss : Cisplatin-ineligible (irreversible outer hair cell ototoxicity). Offer EV + Pembrolizumab.

Peripheral Neuropathy Absent or Grade 1 Grade 1 sensory changes Grade ≥ \ge ≥ 2 neuropathy : Cisplatin-ineligible. Assess suitability for EV + Pembrolizumab (monitor MMAE neurotoxicity) or upfront RC.

Cardiac Function NYHA Class I–II NYHA Class II (carefully hydrated) NYHA Class ≥ \ge ≥ III : Cisplatin-ineligible because of significant heart failure and hydration risk. Offer EV + Pembrolizumab or upfront RC.

Multimodality Management Pathway for cT2–T4aN0M0 MIBC

Clinical & Physiological Stratification Primary Systemic Intervention Definitive Local Treatment Evidence & Guidelines

Cisplatin-Eligible & Immunotherapy-Eligible (eGFR ≥ \ge ≥ 40 mL/min, ECOG 0–1, fit for durvalumab) Perioperative Chemoimmunotherapy (NIAGARA Regimen) : Neoadjuvant Gemcitabine + Cisplatin (split-dose for eGFR 40–59 mL/min) + Durvalumab × \times × 4 cycles, followed by Adjuvant Durvalumab × \times × 8 cycles Radical cystectomy + bilateral standard PLND after recovery from NAC EAU Strong Recommendation (2025/2026); EMA/FDA approved; Phase III NIAGARA trial demonstrates significant EFS (HR 0.68) and OS (HR 0.75) superiority over GC alone.

Eligible for the Selected Cisplatin NAC Regimen, Immunotherapy-Contraindicated (e.g., severe active autoimmune disease) Neoadjuvant Chemotherapy Alone : ddMVAC with G-CSF (six cycles in VESPER) or gemcitabine + cisplatin × \times × 4 cycles Radical cystectomy + bilateral standard PLND after recovery from NAC NAC has a five-year OS benefit (5 percentage points in ABC; 8 in a later EAU-cited analysis). VESPER favoured ddMVAC in its neoadjuvant subgroup; the overall PFS endpoint was not significant.

Cisplatin-Ineligible, Fit for EV + Pembrolizumab (after protocol-specific renal and other fitness assessment) Perioperative Enfortumab Vedotin + Pembrolizumab : 3 neoadjuvant combination cycles; postoperatively 6 EV cycles plus 14 pembrolizumab cycles (pembrolizumab continues alone after EV) Radical Cystectomy + bilateral standard PLND EAU Strong Recommendation (2025/2026); Phase III KEYNOTE-905/EV-303 trial; marked pCR and survival superiority over surgery alone. Carboplatin-containing NAC is not recommended (no established survival benefit).

Unfit for Both Cisplatin and EV + Pembrolizumab (or declining systemic therapy) No Neoadjuvant Systemic Therapy (Carboplatin has NO proven survival benefit in neoadjuvant MIBC) Immediate Upfront Radical Cystectomy + bilateral standard PLND Proceed directly to surgery without futile delays. For pT3/4 or pN+, assess adjuvant cisplatin eligibility; nivolumab is an option if unsuitable/declined, with tumour-cell PD-L1 ≥ \ge ≥ 1% required in Europe.

Selected for Bladder Preservation (Usually solitary cT2–T3a, no extensive/multifocal CIS, no or unilateral hydronephrosis, good bladder function) Concurrent Radiosensitizing Chemotherapy (Cisplatin + 5-FU, or Mitomycin C + 5-FU) Maximal TURBT + radiotherapy (e.g., 64–66 Gy or 55 Gy/20 fractions); salvage cystectomy for invasive persistence/recurrence Trimodal Therapy (TMT); produces 5-year OS comparable to radical cystectomy in highly selected cohorts.

More Advanced or Metastatic Disease (e.g., cT4b, cN2–N3 or cM1a) MDT-directed systemic therapy , including EV + pembrolizumab when suitable Reassess after systemic therapy for delayed consolidation cystectomy or definitive radiation Systemic-intent therapy; consolidation local therapy considered only in complete or major partial responders.